Literature DB >> 10620629

Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.

S T Taylor1, J A Hickman, C Dive.   

Abstract

BACKGROUND: Epigenetic factors (i.e., alterations of gene activity not involving mutations), as well as genetic changes in surviving cancer cells, may play an important role in drug resistance following cancer chemotherapy-a common cause of tumor relapse. Bcl-2 family proteins are central to the regulation of apoptotic cell death and modulate drug sensitivity. We investigated how survival signals in the cellular microenvironment affect the expression, protein conformation, and protein-protein interactions of the Bcl-2 family proteins Bax and Bcl-x(L) and how changes in response to microenvironmental signals alter the response of cancer cells to the drug etoposide.
METHODS: JLP119 human B-lymphoma cells were treated with etoposide (40 microM) and then cultured in the presence of an activating anti-CD40 antibody, vascular cellular adhesion molecule-1 (VCAM-1)-to activate VLA-4 (alpha4beta1) integrin, and interleukin 4. Cell fate was monitored after etoposide treatment with or without these microenvironmental signals. Bcl-x(L) gene transcription and protein levels of Bcl-x(L) and Bax were measured by northern and western blotting, respectively. Nuclear translocation of transcription factor NF-kappaB was monitored by immunofluorescence and inhibited by (E)-capsaicin. Bax conformation and Bax-Bcl-x(L) interactions were monitored by immunofluorescence and immunoprecipitation, respectively.
RESULTS: Microenvironmental survival signals produced statistically significant reductions in etoposide-induced apoptotic cell death, from 84.6% (95% confidence interval [CI] = 76.7%-92.4%) to 21.3% (95% CI = 19.5%-23.0%); P<.001. Activation of surface protein CD40 increased Bcl-x(L) protein levels via an (E)-capsaicin-inhibitable activation of NF-kappaB; i.e. , (E)-capsaicin restored etoposide sensitivity. Interleukin 4 had no effect on Bcl-x(L) protein levels but accelerated the increase in Bcl-x(L) protein associated with CD40 activation. VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.
CONCLUSIONS: Microenvironmental factors reduce the sensitivity of a B-cell lymphoma to etoposide in vitro by modulating the expression and functions of Bax and Bcl-x(L). This interaction may provide a paradigm for epigenetically induced drug resistance in other tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620629     DOI: 10.1093/jnci/92.1.18

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  25 in total

1.  Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate.

Authors:  G W Makin; B M Corfe; G J Griffiths; A Thistlethwaite; J A Hickman; C Dive
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 2.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

3.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

Review 4.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.

Authors:  Guenadi Kouniavsky; Marat Khaikin; Isabel Zvibel; Dov Zippel; Shlomo Brill; Zamir Halpern; Moshe Papa
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 6.  A New View of Pathway-Driven Drug Resistance in Tumor Proliferation.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Trends Pharmacol Sci       Date:  2017-02-27       Impact factor: 14.819

7.  Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.

Authors:  Lucine Fahy; Julien Calvo; Sara Chabi; Laurent Renou; Charly Le Maout; Sandrine Poglio; Thierry Leblanc; Arnaud Petit; André Baruchel; Paola Ballerini; Irina Naguibneva; Rima Haddad; Marie-Laure Arcangeli; Frederic Mazurier; Francoise Pflumio; Benjamin Uzan
Journal:  Blood Adv       Date:  2021-01-26

8.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

Review 9.  Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines.

Authors:  Ga-Young Lee; Jin-Seok Lee; Chang-Gue Son; Nam-Hun Lee
Journal:  Chin J Integr Med       Date:  2020-08-01       Impact factor: 1.978

Review 10.  The role of deubiquitinating enzymes in cancer drug resistance.

Authors:  Parthasaradhireddy Tanguturi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-07       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.